WuXi Vaccines and BravoBio collaborate to accelerate innovative vaccines

The CDMO will provide expertise and capacity to advance BravoBio's vaccine pipeline

The recent outbreaks and epidemics have highlighted the importance of industrial collaboration and partnership. And now, WuXi Vaccines, a joint venture between WuXi Biologics and Shanghai Hile Bio-Technology focused on vaccine CDMO services, and Shanghai BravoBio have signed a Letter of Intent for long-term collaboration on accelerating the development and commercial manufacturing of innovative vaccines.

Specifically, the collaboration will focus on using WuXi Vaccines' end-to-end vaccine development and manufacturing capabilities to advance BravoBio's vaccine pipeline, which aims to address challenges from infectious diseases.

The partnership will see BravoBio utilise WuXi Vaccines’ integrated platforms to conduct preclinical research, GMP manufacturing of clinical supply and global commercial supply for its multiple innovative vaccine candidates.

In addition, the CDMO will leverage its experience and capacity to support the Investigational New Drug (IND) application and commercialication for BravoBio’s vaccine products globally.

Back in November 2019, WuXi Vaccines announced it was investing $240 million and building a new vaccine manufacturing facility in Dundalk, Ireland. The facility got underway in February 2020 and is due to be operational by 2024.